Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction TrialMichiel M Smeenk, Judi N A van Diessen, Thierry N Boellaard, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 7, 2023
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centersJob P van Kooten, Cornedine J de Gooijer, Jan H von der Thüsen, et al.
The Journal of Experimental Medicine|April 10, 2020
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in miceJitendra Badhai, Gaurav Kumar Pandey, Ji-Ying Song, et al.
Cancers|January 21, 2022
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma PatientsLuuk J Schipper, Kim Monkhorst, Kris G Samsom, et al.
Cancers|April 12, 2022
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical RelevanceSimone N Koole, Daan C L Vessies, Milou M F Schuurbiers, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Cancer|October 31, 2023
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerBianca A M H van Veggel, Anthonie J van der Wekken, Marthe S Paats, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2020
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancerSanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combinationLieke L van der Woude, Mark A J Gorris, Inge M N Wortel, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction TrialMichiel M Smeenk, Judi N A van Diessen, Thierry N Boellaard, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 7, 2023
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centersJob P van Kooten, Cornedine J de Gooijer, Jan H von der Thüsen, et al.
The Journal of Experimental Medicine|April 10, 2020
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in miceJitendra Badhai, Gaurav Kumar Pandey, Ji-Ying Song, et al.
Cancers|January 21, 2022
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma PatientsLuuk J Schipper, Kim Monkhorst, Kris G Samsom, et al.
Cancers|April 12, 2022
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical RelevanceSimone N Koole, Daan C L Vessies, Milou M F Schuurbiers, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Cancer|October 31, 2023
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerBianca A M H van Veggel, Anthonie J van der Wekken, Marthe S Paats, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2020
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancerSanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combinationLieke L van der Woude, Mark A J Gorris, Inge M N Wortel, et al.
Pageof 11